Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An aggressive approach to prostatic cancer.

E P Alyea, J E Dees, J F Glenn

    The Journal of Urology
    |July 1, 1977
    PubMed
    Summary

    Aggressive treatment of prostate cancer using surgery, hormonal therapy, and radiation achieved a 50% overall 5-year survival rate. Radical prostatectomy alone demonstrated an 80% 5-year survival for early-stage prostate cancer.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.

    Bone marrow transplantation·2013
    Same author

    Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

    Leukemia·2012
    Same author

    Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.

    Bone marrow transplantation·2012
    Same author

    (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

    Bone marrow transplantation·2011
    Same author

    A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same author

    The use of a fibrinogen coagulum in pyelolithotomy.

    The Journal of urology·2010

    Area of Science:

    • Oncology
    • Urology
    • Surgical Oncology

    Background:

    • Prostate cancer treatment has evolved significantly over 47 years.
    • Duke University Medical Center has employed an aggressive treatment strategy for prostatic malignancies.
    • Early and advanced stages of prostate cancer require diverse therapeutic approaches.

    Purpose of the Study:

    • To evaluate the long-term survival rates of prostate cancer patients treated with various aggressive therapeutic modalities.
    • To assess the efficacy of radical prostatectomy, hormonal therapy, and radiation in managing prostate cancer.
    • To determine the overall survival impact of combining multiple treatment modalities for all stages of prostate cancer.

    Main Methods:

    • Vigorous application of radical prostatectomy (perineal and retropubic routes) with pelvic lymphadenectomy for stages A, B, and C prostate cancer.
    • Hormonal therapy, primarily orchiectomy combined with estrogen therapy, initiated at diagnosis.
    • Integration of radiation therapy and multi-drug chemotherapy for disseminated and progressive disease refractory to other treatments.

    Main Results:

    • Radical prostatectomy yielded an 80% 5-year survival rate in patients with stages A, B, and C prostate cancer.
    • Hormonal therapy demonstrated a 49% 5-year survival rate, exceeding typical averages.
    • A flexible combination of all therapeutic modalities resulted in an overall 50% 5-year survival rate across all patient stages and classifications.

    Conclusions:

    • An aggressive, multi-modal treatment approach significantly improves survival outcomes for prostate cancer patients.
    • Radical prostatectomy is highly effective for localized and locally advanced prostate cancer.
    • Combining various treatment strategies offers a viable option for improving overall survival in advanced or refractory prostate cancer cases.

    Related Experiment Videos